Sex- and age-dependent susceptibility to ventricular arrhythmias in the rat heart ex vivo.
OA: gold
CC-BY-4.0
Abstract
The incidence of life-threatening ventricular arrhythmias, the most common cause of sudden cardiac death (SCD), depends largely on the arrhythmic substrate that develops in the myocardium during the aging process. There is a large deficit of comparative studies on the development of this substrate in both sexes, with a particular paucity of studies in females. To identify the substrates of arrhythmia, fibrosis, cardiomyocyte hypertrophy, mitochondrial density, oxidative stress, antioxidant defense and intracellular Ca2+ signaling in isolated cardiomyocytes were measured in the hearts of 3- and 24-month-old female and male rats. Arrhythmia susceptibility was assessed in ex vivo perfused hearts after exposure to isoproterenol (ISO) and hydrogen peroxide (H2O2). The number of ventricular premature beats (PVBs), ventricular tachycardia (VT) and ventricular fibrillation (VF) episodes, as well as intrinsic heart rate, QRS and QT duration, were measured in ECG signals recorded from the surfaces of the beating hearts. After ISO administration, VT/VFs were formed only in the hearts of males, mainly older ones. In contrast, H2O2 led to VT/VF formation in the hearts of rats of both sexes but much more frequently in older males. We identified several components of the arrhythmia substrate that develop in the myocardium during the aging process, including high spontaneous ryanodine receptor activity in cardiomyocytes, fibrosis of varying severity in different layers of the myocardium (nonheterogenic fibrosis), and high levels of oxidative stress as measured by nitrated tyrosine levels. All of these elements appeared at a much greater intensity in male individuals during the aging process. On the other hand, in aging females, antioxidant defense at the level of H2O2 detoxification, measured as glutathione peroxidase expression, was weaker than that in males of the same age. We showed that sex has a significant effect on the development of an arrhythmic substrate during aging. This substrate determines the incidence of life-threatening ventricular arrhythmias in the presence of additional stimuli with proarrhythmic potential, such as catecholamine stimulation or oxidative stress, which are constant elements in the pathomechanism of most cardiovascular diseases.
My notes (saved in your browser only)
Funding
- funders
- [{'doi': None, 'name': 'National Science Centre, Poland', 'awards': ['2016/21/B/NZ5/01387']}]
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
References (43)
- doi:10.1056/nejmra000650 via crossref
- doi:10.1016/j.jacc.2021.11.066 via crossref
- doi:10.1161/circresaha.121.319893 via crossref
- doi:10.1016/j.jacc.2008.05.058 via crossref
- doi:10.1016/j.amjcard.2005.11.048 via crossref
- doi:10.1016/s0735-1097(97)00355-0 via crossref
- doi:10.1016/j.pcad.2008.06.003 via crossref
- doi:10.1152/physrev.00014.2006 via crossref
- doi:10.1016/j.arr.2022.101722 via crossref
- doi:10.1152/physiol.00019.2006 via crossref
- doi:10.1016/j.bbamcr.2012.08.016 via crossref
- doi:10.4067/s0716-97602004000400005 via crossref
- doi:10.1161/01.res.69.5.1380 via crossref
- doi:10.1152/ajpheart.1993.264.5.h1609 via crossref
- doi:10.1152/ajpheart.00797.2012 via crossref
- doi:10.1113/jphysiol.2013.260521 via crossref
- doi:10.1016/j.biopha.2021.111983 via crossref
- doi:10.1016/j.yjmcc.2014.12.004 via crossref
- doi:10.1152/ajpheart.00299.2010 via crossref
- doi:10.1152/ajpheart.00686.2005 via crossref
- doi:10.1089/rej.2008.0771 via crossref
- doi:10.1152/ajpheart.1998.275.6.h2087 via crossref
- doi:10.1152/ajpheart.2002.282.1.h256 via crossref
- doi:10.1161/circresaha.108.184457 via crossref
- doi:10.1093/cvr/cvp246 via crossref
- doi:10.3390/ijms21124200 via crossref
- doi:10.1161/strokeaha.106.477406 via crossref
- doi:10.3389/fcell.2022.1010232 via crossref
- doi:10.1084/jem.192.7.1001 via crossref
- doi:10.1038/s41419-022-04906-6 via crossref
- doi:10.1002/bies.201800005 via crossref
- doi:10.1111/jcmm.13038 via crossref
- doi:10.1016/j.mad.2023.111797 via crossref
- doi:10.1590/s0100-879x2002000900008 via crossref
- doi:10.1016/s0024-3205(96)00663-7 via crossref
- doi:10.4077/cjp.2011.amm080 via crossref
- doi:10.1016/j.maturitas.2016.01.015 via crossref
- doi:10.1016/0005-2736(86)90233-6 via crossref
- doi:10.1113/expphysiol.2011.057752 via crossref
- doi:10.1152/ajpheart.00579.2009 via crossref
- doi:10.1126/science.275.5301.841 via crossref
- doi:10.1016/j.pharmthera.2013.04.008 via crossref
- doi:10.1111/j.1469-7793.1999.109ad.x via crossref
Source provenance
- crossref
- last seen: 2026-08-12T06:42:47.972778+00:00
- europepmc
- last seen: 2026-08-23T09:30:01.253652+00:00
License: CC-BY-4.0
· commercial use OK
· attribution required
Per Europe PMC
Per Europe PMC